2026 20th WRIB
TriApex recently participated in the 20th Annual Workshops on Recent Issues in Bioanalysis (WRIB), held April 13–17, 2026 in Dallas, Texas, USA. The event brought together over 1,200 professionals from pharmaceutical and biotechnology companies, contract research organizations (CROs), and regulatory agencies to explore the latest developments in bioanalysis.
Organized by the California Bioanalysis Forum (CFABS), WRIB is one of the most influential international conferences in the field of bioanalysis. The meeting brings together leading scientists from pharmaceutical and biotechnology companies, contract research organizations (CROs), and global regulatory agencies to discuss the latest advances, regulatory expectations, and scientific challenges in bioanalysis.
At the meeting, TriApex actively contributed to the scientific dialogue through poster presentations and interactions with industry experts, sharing the company’s latest innovations in bioanalytical methodologies supporting next-generation therapeutics.
Poster Highlights
Sensitive Quantification of RISC-Loaded siRNA
One poster titled “Establishment of a Highly Sensitive Stem-Loop RT-qPCR Method for RISC-Loaded siRNA in Pharmacokinetic and Pharmacodynamic Studies” presented a novel approach for quantifying functionally active siRNA incorporated into the RNA-induced silencing complex (RISC).
The method integrates RNA immunoprecipitation (RIP) with stem-loop RT-qPCR, enabling selective capture of Ago2-associated RISC complexes and sensitive detection of RISC-loaded siRNA.
This platform provides a powerful tool for evaluating the functional pharmacokinetics and pharmacodynamics of RNAi therapeutics.
Poster Highlights
Integrated Biomarker Platform for Activin E / INHBE
TriApex also presented a poster titled “Development of Integrated qPCR and ELISA Bioanalytical Platforms for Pharmacodynamic Biomarker Assessment of INHBE or Activin E-Targeting”.
The study established an integrated analytical platform combining RT-qPCR for INHBE mRNA detection and sandwich ELISA for Activin E protein quantification. Both assays demonstrated strong analytical performance and were successfully applied to pharmacodynamic studies in cynomolgus monkeys, showing dose-dependent reductions in INHBE expression and circulating Activin E levels.
These complementary assays provide an effective bioanalytical solution for supporting the translational development of therapies targeting metabolic disease pathways.
Expanding Global Bioanalytical Capabilities
With the establishment of the TriApex U.S. laboratory, our global bioanalytical service network has further expanded to support clients across early discovery, nonclinical studies, and clinical development. The TriApex US Lab provides integrated bioanalytical solutions covering the full development lifecycle of biotherapeutics. Our services support programs from:
•Early screening and candidate selection
•IND-enabling nonclinical studies
•Clinical development (Phase I–III)
免责声明：本文仅作信息交流而非商业盈利之目的，内容仅供分享。
尚红网提示：文章来自网络，不代表本站观点。
- 上一篇：宫玉振：想打胜仗，老板要少干预一线
- 下一篇：没有了
相关文章
热点资讯